Mercer Global Advisors
ABUS icon

Mercer Global Advisors’s Arbutus Biopharma ABUS Stock Holding History

Mercer Global Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.8K Sell
18,085
-1,260
-7% -$5.53K ﹤0.01% 3447
2026
Q1 		$87.1K Sell
19,345
-25,775
-57% -$113K ﹤0.01% 3051
2025
Q4 		$217K Buy
45,120
+6,161
+16% +$27.7K ﹤0.01% 2493
2025
Q3 		$177K Buy
38,959
+3,280
+9% +$12K ﹤0.01% 2418
2025
Q2 		$110K Buy
35,679
+15,179
+74% +$50.4K ﹤0.01% 2148
2025
Q1 		$71.5K Hold
20,500
– – ﹤0.01% 2078
2024
Q4 		$67K Buy
+20,500
New +$75.4K ﹤0.01% 2069

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Mercer Global Advisors's ABUS Position: Q2 2026 in Review

Mercer Global Advisors reduced its Arbutus Biopharma (ABUS) stake by 6.5% in Q2 2026, selling an estimated $5.53K and leaving 18,085 shares worth $86.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3447.

Mercer Global Advisors first reported a position in ABUS in Q4 2024 and has held it in 7 quarters since. The position peaked at $217K in Q4 2025. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Mercer Global Advisors held 18,085 shares of Arbutus Biopharma worth $86.8K as of Q2 2026.
  • Mercer Global Advisors sold 1,260 Arbutus Biopharma shares in Q2 2026, an estimated $5.53K.
  • Arbutus Biopharma made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #3447 holding.
  • Mercer Global Advisors first reported a position in Arbutus Biopharma in Q4 2024 and has held it in 7 quarters since.
  • Mercer Global Advisors's Arbutus Biopharma position peaked at $217K in Q4 2025.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.